
CLAIMS

1. Use of compounds of the general formula (A):




(A)


wherein


R_1 is -C(O)-R_2-C(O)- or -R_2-C(O)- group, where R_2 is -$(CH_2)_n$- group optionally substituted with one or two C_1-C_6 alkyls, or phenyl,


n is an integer from 0 to 4;


wherein compounds are selected from the group consisting of compounds of formula


I 


II 


III 


IV 


V 

VI 

VII 

VIII 

IX 

X 

or pharmaceutically acceptable salts, hydrates, or solvates thereof in the manufacture of a medicament, wherein the medicament acts as a glutaminyl cyclase inhibitor.

2. The use according to claim 1, wherein the medicament is for the prevention and/or treatment of a disorder associated with glutaminyl cyclase activity.

3. The use according to claim 1, wherein the medicament is for the prevention and/or treatment of a disorder associated with aberrant activity of cells of an immune system.

4. The use according to claim 1, wherein the medicament is for the prevention and/or treatment of a disorder associated with aberrant chemotaxis of cells of an immune system.

5. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is a disease selected from lung, respiratory tract and abdominal diseases, radiation sickness, and/or pain syndrome.

6. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is bronchial asthma, acute or chronic bronchitis, pharyngitis, lung emphysema, rhinitis, rhinosinusitis, chronic obstructive pulmonary disease, or acut lung injury.

7. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is fever.

8. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is atopic dermatitis.

9. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is autoimmune diseases, in particular psoriasis, Crohn's disease and ulcerative colitis.

10. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is metabolic disorders, in particular obesity, metabolic syndrome and non-alcohol fatty liver disease, nephropathy (in particular, diabetic nephropathy).

11. The use according to claim 2 or 3, wherein the disorder associated with the activity of glutaminyl cyclase and/or aberrant activity of cells of the immune system is peritonitis.

12. The use according to any one of the preceding claims, wherein the medicament further comprises at least one other active agent.

13. The use according to claim 12, wherein the at least one other active agent is selected from the group comprising antibacterial, cytostatic and cytotoxic agents, agents inhibiting symptoms or side effects of active agents, and a combination thereof.